Anglo-Swedish pharmaceutical company AstraZeneca (LSE: AZN) is considering a $10 billion bid for US cancer drugmaker Medivation (Nasdaq: MDVN), according to reports.
It comes after Medivation, which makes blockbuster prostate cancer drug Xtandi (enzalutamide), successfully fought off a three-month hostile takeover attempt by French pharma major Sanofi (Euronext: SAN).
Last week it was announced that Medivation had entered into confidentiality agreements Sanofi and a number of other companies, including US biotech firm Celgene (Nasdaq: CELG) and biopharmaceutical giant Pfizer (NYSE: PFE).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze